AU2013218441A1 - Lupane triterpenoid derivatives and pharmaceutical use thereof - Google Patents

Lupane triterpenoid derivatives and pharmaceutical use thereof Download PDF

Info

Publication number
AU2013218441A1
AU2013218441A1 AU2013218441A AU2013218441A AU2013218441A1 AU 2013218441 A1 AU2013218441 A1 AU 2013218441A1 AU 2013218441 A AU2013218441 A AU 2013218441A AU 2013218441 A AU2013218441 A AU 2013218441A AU 2013218441 A1 AU2013218441 A1 AU 2013218441A1
Authority
AU
Australia
Prior art keywords
compound
independently
mmol
optionally substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013218441A
Other languages
English (en)
Inventor
Feng Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FENG Qiaodi
JIANGXI QINGFENG PHARMACEUTICAL Inc
Original Assignee
FENG QIAODI
JIANGXI QINGFENG PHARMACEUTICAL Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FENG QIAODI, JIANGXI QINGFENG PHARMACEUTICAL Inc filed Critical FENG QIAODI
Publication of AU2013218441A1 publication Critical patent/AU2013218441A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013218441A 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof Abandoned AU2013218441A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201210027090.4 2012-02-08
CN201210027090 2012-02-08
CN201310014849.XA CN103242413B (zh) 2012-02-08 2013-01-15 Lupane三萜系衍生物及其药学用途
CN201310014849X 2013-01-15
PCT/CN2013/071100 WO2013117137A1 (en) 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
AU2013218441A1 true AU2013218441A1 (en) 2014-07-24

Family

ID=48922317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013218441A Abandoned AU2013218441A1 (en) 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof

Country Status (11)

Country Link
US (1) US9428542B2 (cg-RX-API-DMAC7.html)
EP (1) EP2812343B1 (cg-RX-API-DMAC7.html)
JP (1) JP5872074B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140126739A (cg-RX-API-DMAC7.html)
CN (1) CN103242413B (cg-RX-API-DMAC7.html)
AU (1) AU2013218441A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014018953A8 (cg-RX-API-DMAC7.html)
CA (1) CA2860581A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491479A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013117137A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201405819B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
AU2015346303B2 (en) * 2014-11-14 2018-03-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
US9914747B2 (en) 2014-11-14 2018-03-13 VIIV Healthcare UK (No.5) Limited Extended betulinic acid analogs
RU2017118576A (ru) * 2014-11-14 2018-12-14 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД C-17-арил-замещённые аналоги бетулиновой кислоты
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
WO2018029602A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-28 heterocycle derivatives as hiv inhibitors
WO2018029604A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
WO2018029610A1 (en) * 2016-08-09 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-17 n-amide derivatives as hiv inhibitors
WO2018065930A1 (en) * 2016-10-05 2018-04-12 Hetero Labs Limited C-3 triterpenone with c-17 reverse amide derivatives as hiv inhibitors
WO2018069857A1 (en) * 2016-10-12 2018-04-19 Hetero Labs Limited C-3 novel triterpenone with c-17 reverse amide heterocycle derivatives as hiv inhibitors
WO2019150300A1 (en) 2018-02-02 2019-08-08 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
CN114369134B (zh) * 2020-10-15 2024-12-31 江西青峰药业有限公司 一种Lupane三萜系衍生物葡甲胺盐无定型物及其制备方法和应用
CN114369136A (zh) * 2020-10-15 2022-04-19 江西青峰药业有限公司 一种Lupane三萜系衍生物的碱加成盐及其应用
CN115504947B (zh) * 2022-08-23 2024-04-26 山东和源制药有限公司 一种呋喃酮酸的制备方法
CN116041415B (zh) * 2023-02-01 2023-08-18 吉林农业大学 一种裂环羽扇豆烷衍生物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008057420A2 (en) * 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
WO2009073818A1 (en) * 2007-12-04 2009-06-11 Myriad Genetics, Inc. Compounds and therapeutic use thereof
CA2711424A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
AU2008342536A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel C-21-keto lupane derivatives preparation and use thereof
SG182769A1 (en) 2010-02-11 2012-09-27 Glaxosmithkline Llc Derivatives of betulin
JO3387B1 (ar) * 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين

Also Published As

Publication number Publication date
KR20140126739A (ko) 2014-10-31
CN103242413A (zh) 2013-08-14
JP5872074B2 (ja) 2016-03-01
JP2015505545A (ja) 2015-02-23
EP2812343A1 (en) 2014-12-17
US20150011517A1 (en) 2015-01-08
CN103242413B (zh) 2015-08-26
EP2812343B1 (en) 2019-03-13
WO2013117137A1 (en) 2013-08-15
BR112014018953A8 (pt) 2017-07-11
US9428542B2 (en) 2016-08-30
CA2860581A1 (en) 2013-08-15
BR112014018953A2 (cg-RX-API-DMAC7.html) 2017-06-20
EP2812343A4 (en) 2015-12-02
EA201491479A1 (ru) 2014-11-28
HK1202553A1 (en) 2015-10-02
ZA201405819B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
EP2812343B1 (en) Lupane triterpenoid derivatives and pharmaceutical use thereof
ES3023366T3 (en) Heteroalkyl dihydroquinoline sulfonamide compounds
AU2020384883B2 (en) Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
CN118234733A (zh) 一类五元杂环并嘧啶类衍生物及其作为泛kras突变抑制剂的用途
CA3137025A1 (en) Bicyclic compounds
CA2963973C (en) Macrocylic compounds as ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
AU2016417542B2 (en) Imidazopyridine thioglycolic acid derivative, preparation method therefor and application thereof
CA3073543A1 (en) Benzosulfonyl compounds
CN112707905B (zh) 一种三并杂环化合物及其制备方法和用途
CN112851663B (zh) 一种并杂环化合物及其用途
BRPI0923670A2 (pt) inibidores da atividade de proteÍna tirosina quinase e seu uso, bem como composiÇço compreendendo os mesmos
BRPI0716641A2 (pt) Moduladores de receptor de glicocorticóide, e/ou ap-1, e/ou atividade de nf-kb e uso destes
AU2022275470B2 (en) Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
WO2022087008A1 (en) Tertiary carboxamide compounds
AU2020204717B2 (en) Methods and materials for increasing transcription factor EB polypeptide levels
RU2656209C2 (ru) Терапевтически активные производные оксазолина
CA3218442A1 (en) Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
CA3063804A1 (en) A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof
WO2021163629A1 (en) Inhibitors of ulk1/2 and methods of using same
AU2023302462A1 (en) Pi3k inhibitor, preparation method therefor, and use thereof
AU2018258588B2 (en) Inhibitors of TRIM33 and methods of use
CN113966331B (zh) 含脲结构的三芳环化合物及其应用
CA2702990A1 (en) Compounds for inhibiting ksp kinesin activity
CN110143948B (zh) Cdk4/6抑制剂、其药物组合物、制备方法及应用
CA3212918A1 (en) 8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period